Cisplatin Market Size, Share, Growth, and Industry Analysis, By Type (Tablets, Injection), By Application (Testicular Cancer, Osteosarcoma, Breast Cancer), Regional Insights and Forecast from 2026 to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

CISPLATIN MARKET OVERVIEW

The global Cisplatin Market size estimated at USD 1.73 billion in 2026 and is projected to reach USD 3.16 billion by 2035, growing at a CAGR of 6.92% from 2026 to 2035.

The global Cisplatin Market remains an important segment of oncology pharmaceuticals because cisplatin is a platinum-based antineoplastic medicine used in multiple cancer-treatment protocols. The WHO Model List of Essential Medicines includes cisplatin injection in strengths of 10 mg/10 mL, 20 mg/20 mL, 50 mg/50 mL, and 100 mg/100 mL for indications including testicular germ-cell tumors, osteosarcoma, non-small-cell lung cancer, cervical cancer, and other malignancies. Injection formulations represented 72.11% of the global Cisplatin Market in 2023, while testicular cancer represented 34.82%.

Cisplatin demand in the United States is supported by established oncology infrastructure, generic-drug procurement, and use across hospital-based chemotherapy programs. The U.S. experienced a significant cisplatin shortage beginning in February 2023, highlighting the strategic importance of reliable sterile-injectable manufacturing. By June 2024, the FDA determined that national cisplatin supply exceeded demand and reported 7 approved manufacturers after additional supply interventions and market re-entry. U.S. products commonly use a 1 mg/mL concentration, including 50 mL and 100 mL presentations.

KEY FINDINGS

LATEST TRENDS

The latest Cisplatin Market trends are centered on supply security, injectable manufacturing, combination oncology, toxicity management, and improved treatment delivery. The 2023 U.S. shortage demonstrated that mature generic oncology products can remain strategically vulnerable when sterile manufacturing capacity is concentrated among a limited number of suppliers. The FDA worked with 5 cancer-drug manufacturers during the shortage and helped another manufacturer re-enter the market, ultimately contributing to 7 approved manufacturers by June 2024. Injection remains the dominant formulation, accounting for 72.11% of the global Cisplatin Market in 2023. U.S. products commonly use a 1 mg/mL concentration, with 50 mL and 100 mL vial configurations available.

This supports demand from hospitals, oncology centers, and institutional pharmacy systems where cisplatin is administered intravenously under clinical supervision. Combination treatment is another important trend. In March 2024, the FDA approved nivolumab in combination with cisplatin and gemcitabine for first-line treatment of adults with unresectable or metastatic urothelial carcinoma, expanding the strategic role of cisplatin-based chemotherapy within modern immunotherapy regimens. Toxicity-reduction research is also influencing Cisplatin Market development. A systematic review covering 51 eligible studies found that cisplatin-induced acute kidney injury remains a significant concern, while magnesium supplementation showed a nephroprotective effect in 1,841 patients across the analyzed observational studies.

MARKET DYNAMICS

Driver

Rising global cancer treatment demand and continued reliance on cisplatin-based chemotherapy protocols.

Cisplatin remains embedded in treatment pathways for multiple malignancies, supporting a recurring pharmaceutical demand base. The WHO 2023 Model List identifies cisplatin for 9 cancer-related uses, including cervical cancer, head and neck cancer, low-grade glioma, nasopharyngeal cancer, non-small-cell lung cancer, osteosarcoma, ovarian germ-cell tumors, and testicular germ-cell tumors. Testicular cancer is particularly important for the Cisplatin Market because the segment represented 34.82% of global market share in 2023. Cisplatin-based combinations have historically produced strong outcomes in germ-cell tumors, making treatment protocols relatively established compared with many newer oncology indications.

Drivers Impact Analysis*

Restraint

Cisplatin-associated nephrotoxicity, ototoxicity, and other dose-limiting adverse effects.

Cisplatin's principal market restraint is its clinically significant toxicity profile. A systematic review reported cisplatin-induced acute kidney injury in approximately 20%-40% of exposed patients, despite preventive measures. Another systematic review found reported nephrotoxicity incidence varying from 20% to 70%, depending on patient populations, treatment exposure, and toxicity definitions. Long-term renal effects can also influence treatment planning. A childhood-cancer meta-analysis found pooled prevalence of reduced glomerular filtration rate at 29% using a modern threshold of 90 mL/min/1.73 m², while pooled hypomagnesemia prevalence was 37%. These figures demonstrate why renal monitoring can remain relevant after treatment completion.

Restraints Impact Analysis*

Development of safer delivery systems, combination therapies, and supply-chain-focused manufacturing

Opportunity

The Cisplatin Market has significant opportunities in drug-delivery innovation and toxicity reduction. Conventional cisplatin is primarily administered intravenously, and injection formulations accounted for 72.11% of the global market in 2023. This concentration creates opportunities for improved formulations, controlled delivery systems, localized administration, and technologies designed to maintain antitumor activity while reducing systemic exposure.

Combination therapy represents another opportunity. In 2024, U.S. regulatory approval of nivolumab with cisplatin and gemcitabine for metastatic or unresectable urothelial carcinoma demonstrated how established chemotherapy can be incorporated into modern immunotherapy treatment pathways.

Maintaining reliable sterile injectable supply while controlling manufacturing complexity and quality risk

Challenge

Cisplatin is an older generic medicine, but its manufacturing requirements remain demanding. FDA analysis identifies manufacturing quality issues as the most common reason for drug shortages, while older sterile injectables are especially vulnerable because relatively few production lines can manufacture them and raw-material suppliers may have limited capacity.

The 2023 U.S. shortage showed the commercial and operational consequences of these constraints. Hospitals reported difficulty obtaining cisplatin while manufacturers worked to increase production. Temporary importation was used to supplement supply, and by June 2024 national availability exceeded demand. Another challenge is raw-material exposure.

•   
•   
  

  Download Free Sample to learn more about this report

    

COMMERCIAL COFFEE VENDING MACHINES MARKET SEGMENTATION

By Type

Based on type the market can be categorized into Tablets, Injection

• Tablets: Tablets represent a smaller portion of the Cisplatin Market than injectable products, although some market-report classifications continue to include tablets as a distinct type. The global dosage-form data available for 2023 identify injections at 72.11%, leaving 27.89% for other dosage forms under that specific two-category framework. However, this residual category should not automatically be interpreted as clinically equivalent to conventional oral cisplatin tablets because cisplatin's established clinical use is predominantly parenteral. The commercial importance of oral formulations is therefore connected more strongly to pharmaceutical innovation and alternative delivery research than to established mainstream cisplatin administration.

• Injection: Injection is the dominant Cisplatin Market type, holding 72.11% of global market share in 2023. The dominance reflects cisplatin's established intravenous administration pathway, rapid systemic availability, controlled hospital dosing, and use in combination chemotherapy. U.S. labeling includes 1 mg/mL cisplatin injection in 50 mL and 100 mL vial presentations, demonstrating the standardized nature of commercial injectable products. The injection segment is also strategically important because supply disruptions have direct clinical consequences. During the U.S. shortage beginning in February 2023, regulators supported manufacturers and temporary importation to improve availability.

By Application

Based on application the market can be categorized into Testicular Cancer, Osteosarcoma, Breast Cancer

• Testicular Cancer: Testicular cancer was the leading specified application in the global Cisplatin Market, accounting for 34.82% of market share in 2023. Cisplatin is particularly important in germ-cell tumor treatment because platinum-based chemotherapy has been integrated into established regimens for decades. The market therefore benefits from strong physician familiarity, standardized protocols, and continued demand from oncology centers treating testicular germ-cell tumors. The WHO Model List specifically includes cisplatin for testicular germ-cell tumors, reinforcing its importance in essential oncology treatment.

• Osteosarcoma: Osteosarcoma represents another important application for cisplatin and is specifically included in the WHO Model List of Essential Medicines. Treatment commonly involves multidrug chemotherapy protocols in which cisplatin may be combined with other cytotoxic agents. Its use in osteosarcoma supports demand from specialist oncology hospitals, pediatric cancer centers, orthopedic oncology units, and tertiary-care institutions. The commercial importance of this application is strengthened by the clinical complexity of osteosarcoma management. Patients may require treatment before surgery, after surgery, or during advanced disease management, creating multiple potential points of cisplatin utilization.

• Breast Cancer: Breast cancer represents a specified Cisplatin Market application in several commercial market classifications, although cisplatin is not the principal platinum medicine for all breast-cancer settings. Platinum chemotherapy can be relevant in selected patient populations, particularly where tumor biology and treatment strategy support platinum-based approaches. This creates a targeted rather than universal demand base for cisplatin. Commercial demand is influenced by clinical guidelines, biomarker-driven treatment selection, combination regimens, and competition from other chemotherapy agents.

•   
•   
  Download Free Sample to learn more about this report

    

CISPLATIN MARKET REGIONAL INSIGHTS

• North America

North America represents the leading regional market for cisplatin, supported by advanced oncology infrastructure, high hospital utilization, established generic procurement, and extensive regulatory oversight. Commercial market assessments identify North America as the largest Cisplatin Market region, while the broader platinum-based cancer-drug market accounted for approximately 39.6% of global share in 2022.

The United States is the primary regional contributor because it has a large network of cancer centers and hospital pharmacies. The U.S. cisplatin shortage during 2023 significantly influenced market dynamics. The shortage was formally announced on February 10, 2023, and the FDA worked with 5 manufacturers to increase manufacturing capacity. Temporary importation was also permitted, while another manufacturer returned to the market.

• Europe

Europe maintains a significant Cisplatin Market position because of established cancer-treatment systems, widespread hospital pharmacy networks, generic medicine adoption, and long-standing use of platinum chemotherapy. Cisplatin is included in international essential-medicine frameworks, and European oncology practice uses cisplatin across several solid tumors. The medicine's long clinical history, with initial U.S. approval dating to 1978, demonstrates the maturity of the product category.

European demand is also supported by the use of cisplatin in combination regimens. In 2024, European regulators considered expansion of nivolumab plus cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma following the U.S. approval of the combination. Such treatment developments reinforce the continuing role of cisplatin alongside immunotherapy rather than positioning it only as a legacy chemotherapy product.

• Asia-Pacific

Asia-Pacific is a major Cisplatin Market region because it combines substantial cancer-treatment demand with significant pharmaceutical manufacturing capacity. China and India are particularly important for generic oncology production and active pharmaceutical ingredient supply, while Japan, South Korea, and Australia maintain sophisticated oncology systems.

Commercial assessments identify Asia-Pacific as the fastest-growing regional market, while North America remains the leading region by current share. China is strategically important because several manufacturers identified in the global competitive landscape operate in the country, including Jiangsu Haosen Pharmaceutical Group, Qilu Pharmaceutical, Yunnan Plant Pharmaceutical, Yunnan Biological Valley Pharmaceutical, and Dezhou De Pharmaceutical.

• Middle East & Africa

The Middle East & Africa Cisplatin Market is influenced by cancer incidence, oncology infrastructure, medicine procurement, import dependence, and government healthcare investment. Demand is concentrated in countries with established tertiary-care hospitals and oncology centers, including Saudi Arabia, the United Arab Emirates, South Africa, Qatar, and other major healthcare markets.

Commercial segmentation commonly identifies these countries as important components of the regional cisplatin landscape. Hospital-based treatment is particularly important because cisplatin is generally administered intravenously and requires clinical monitoring. The global injection segment represented 72.11% of the market in 2023, reinforcing the importance of hospitals and specialized cancer-treatment facilities in regions where cisplatin is used.

KEY INDUSTRY PLAYERS

The global Cisplatin Market consists of leading pharmaceutical manufacturers and oncology drug providers focused on ensuring reliable access to platinum-based chemotherapy treatments. Companies such as Pfizer, Hospira, Fresenius Kabi, and Teva are strengthening their market presence through established cisplatin injection portfolios and extensive pharmaceutical distribution networks. Gland Pharma, Mylan Pharmaceuticals, and Alvogen are supporting the market through generic oncology medicines and injectable manufacturing capabilities.

Manufacturers including Qilu Pharmaceutical, Jiangsu Haosen Pharmaceutical Group, Yunnan Plant Pharmaceutical, Yunnan Biological Valley Pharmaceutical, and Dezhou De Pharmaceutical are focusing on cisplatin production for domestic and international oncology markets. West-Ward Pharmaceuticals, WG Critical Care, Bedford Pharmaceuticals, Athenex Pharmaceutical, and Omega Laboratories are also contributing to the competitive landscape through generic pharmaceutical and sterile injectable capabilities. The competitive environment is driven by increasing demand for cancer treatments, the continued use of cisplatin-based chemotherapy protocols, hospital procurement requirements, manufacturing reliability, and the development of improved oncology drug-delivery technologies.

LIST OF TOP CISPLATIN COMPANIES

• Eli Lilly and Company
• Hospira
• Pfizer
• Bedford Pharmaceuticals
• Alvogen
• Athenex Pharmaceutical
• Gland Pharma (Fosun Pharma)
• West-Ward Pharmaceuticals
• WG Critical Care
• David Bull Laboratories
• Omega Laboratories
• Fresenius Kabi
• TEVA
• Mylan Pharmaceuticals
• Yunnan Plant Pharmaceutical
• Yunnan Biological Valley Pharmaceutical
• Dezhou de Pharmaceutical
• Jiangsu Haosen Pharmaceutical Group
• Qilu Pharmaceutical

MARKET LEADERSHIP MATRIX: CISPLATIN MARKET

LEADER INSIGHTS

• Eli Lilly and Company: David A. Ricks, Chair and Chief Executive Officer, said Lilly is expanding manufacturing capacity in response to increasing demand and growing confidence in its pipeline, with investments designed to support next-generation medicines across cardiometabolic health, oncology, immunology and neuroscience. His comments indicate that anticipated patient demand and continued pipeline expansion are driving large-scale capacity investments and strengthening long-term pharmaceutical supply capabilities. (Published: June 18, 2026 | Source: Eli Lilly and Company)

• Teva Pharmaceutical Industries: Richard Francis, President and Chief Executive Officer, emphasized that Teva's generics business has returned to growth while the company is accelerating its transition toward an innovation-led biopharmaceutical model. He highlighted multiple complex generics, biosimilars and a late-stage pipeline as important future growth drivers, supported by broad pharmacy, hospital, wholesaler and payer relationships across more than 55 markets. (Published: February 17, 2026 | Source: Teva Pharmaceutical Industries)

• Pfizer: Albert Bourla, Chairman and Chief Executive Officer, emphasized that Pfizer's strengthened oncology capabilities following the Seagen acquisition are creating significant opportunities to advance cancer care, while digital technologies and artificial intelligence are being applied across drug discovery, clinical development, manufacturing and regulatory processes. His outlook points to continued technology adoption and strategic investment as important factors in expanding oncology innovation and addressing substantial unmet patient needs. (Published: 2026 | Source: Pfizer Annual Review)

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment opportunities in the Cisplatin Market are increasingly concentrated in manufacturing resilience, sterile injectable capacity, quality systems, oncology distribution, and formulation technology rather than conventional discovery of a new cisplatin molecule. The 2023 U.S. shortage demonstrated the commercial importance of maintaining adequate sterile-injectable production capacity, while the FDA's 2024 resolution after collaboration with 5 manufacturers highlighted the value of diversified supply. Investors can focus on manufacturers with validated injectable facilities, multiple production locations, reliable API sourcing, and established regulatory approvals.

The presence of 7 approved manufacturers in the United States by June 2024 illustrates the importance of supplier diversification. Asia-Pacific offers additional investment potential because China and India are important manufacturing centers. Qilu Pharmaceutical's 2024 U.S. cisplatin product illustrates how Asian manufacturing can support regulated international markets. Another opportunity involves toxicity-reduction technology. Cisplatin-associated acute kidney injury affects approximately 20%-40% of exposed patients, creating demand for renal-protection protocols, hydration systems, magnesium supplementation, monitoring technologies, and potentially improved drug-delivery platforms.

NEW PRODUCT DEVELOPMENT

New product development in the Cisplatin Market is increasingly focused on improving delivery, reducing toxicity, and integrating cisplatin with targeted or immune-based treatment strategies. Traditional cisplatin injection remains dominant at 72.11% of the market, so formulation innovation must demonstrate a meaningful clinical or operational advantage over established injectable products. Nanotechnology represents one research direction. A 2024 study described a cisplatin-loaded magnetoliposome system combining cisplatin delivery with magnetic hyperthermia. The research used tumor models and investigated temperatures above 41°C, with the objective of increasing tumor-cell killing while improving localized treatment effects.

Otoprotective development is another important area. A 2025 systematic review evaluated randomized controlled trials investigating intratympanic N-acetylcysteine for prevention of cisplatin-associated ototoxicity, reflecting continued research into maintaining cisplatin efficacy while reducing hearing-related complications. Combination therapy is advancing simultaneously. In 2024, nivolumab combined with cisplatin and gemcitabine received U.S. approval for first-line treatment of unresectable or metastatic urothelial carcinoma. In January 2025, Sichuan Kelun-Biotech received Chinese NMPA authorization for tagitanlimab in combination with cisplatin and gemcitabine for first-line recurrent or metastatic nasopharyngeal cancer.

FIVE RECENT DEVELOPMENTS (2023-2025)

• June 2023: Qilu Pharmaceutical introduced a new cisplatin supply initiative for the U.S. market. The company supplied cisplatin injection following FDA authorization for temporary importation during the U.S. chemotherapy shortage. The initiative provided an additional source of sterile injectable cisplatin, supported oncology treatment continuity, and strengthened international supply-chain resilience for essential platinum-based chemotherapy.
• August 2023: Fresenius Kabi expanded cisplatin availability in the U.S. market. The company initiated temporary importation of CISplatin Injection BP at 50 mg/50 mL, manufactured in India, to address the critical shortage. The initiative strengthened emergency supply capacity, diversified sourcing, and helped hospitals maintain access to an established platinum-based chemotherapy medicine during significant supply-chain disruption.
• November 2023: Accord Healthcare resumed manufacturing of cisplatin for the U.S. market. The company restarted production amid continuing chemotherapy shortages, restoring an established supplier to the oncology pharmaceutical supply chain. The development supported availability for patients receiving cisplatin-based treatment and demonstrated the importance of production recovery, manufacturing capacity, and reliable sterile injectable supply for essential cancer medicines.
• November 2024: Researchers developed a cisplatin-loaded magnetoliposome technology with magnetic hyperthermia. The experimental platform combined cisplatin with magnetic nanoparticles inside liposomes and used electromagnetic fields to generate localized heating above 41°C. In lung-tumor models, the combined treatment improved survival compared with soluble cisplatin or hyperthermia alone, highlighting opportunities for targeted cisplatin delivery.
• February 2025: Fennec Pharmaceuticals and Norgine Pharmaceuticals launched PEDMARQSI in Germany to address cisplatin-induced ototoxicity. The sodium thiosulfate injection became commercially available for pediatric patients aged 1 month to under 18 years with localized, non-metastatic solid tumors. Phase 3 studies demonstrated an approximately 50% reduction in cisplatin-induced ototoxicity, strengthening supportive-care options around cisplatin chemotherapy.

CISPLATIN MARKET REPORT COVERAGE

The Cisplatin Market report covers product segmentation, cancer applications, regional performance, competitive positioning, manufacturing developments, supply-chain conditions, investment opportunities, and product innovation. The segmentation includes 2 principal product categories specified in the requested market framework—tablets and injection—and 3 principal applications consisting of testicular cancer, osteosarcoma, and breast cancer. Global commercial assessments identify injection as the dominant dosage category at 72.11% of 2023 market share and testicular cancer as the leading application at 34.82%. Geographically, the report evaluates 4 major regions: North America, Europe, Asia-Pacific, and Middle East & Africa. North America receives particular attention because of the U.S. cisplatin shortage beginning in 2023, followed by supply normalization in 2024.

The analysis also covers regulatory actions involving 7 U.S. approved manufacturers and temporary importation mechanisms used to stabilize supply. The competitive section evaluates 19 companies specified in the market framework, including Pfizer, Hospira, Fresenius Kabi, Teva, Gland Pharma, Qilu Pharmaceutical, Jiangsu Haosen Pharmaceutical Group, and other generic oncology manufacturers. Company analysis focuses on manufacturing presence, product availability, regulatory positioning, formulation capability, geographic reach, and supply resilience rather than revenue. The report additionally covers cisplatin toxicity, including approximately 20%-40% acute kidney-injury incidence reported in a systematic review and approximately 49.21% pooled ototoxic hearing-loss prevalence for cisplatin-only exposure in a separate meta-analysis.